T1	tradename 113 120	ZEVALIN
T2	tradename 183 201	ZEVALIN. ZEVALIN
T3	nanoparticle 203 224	ibritumomab tiuxetan)
T4	routeofadministration 239 250	intravenous
T5	fdaapprovaldate 278 282	2002
T6	adversereaction 486 505	Infusion Reactions,
T7	co-administereddrug 547 556	rituximab
T8	adversereaction 605 615	Cytopenias
T9	adversereaction 656 701	Severe Cutaneous and Mucocutaneous Reactions,
T10	tradename 729 736	Zevalin
T11	activeingredient 814 818	Y-90
T12	tradename 819 827	Zevalin.
T13	tradename 1098 1098	
T14	chemoclass 1104 1117	CD20-directed
T15	tradename 1172 1179	Zevalin
T16	indication 1304 1340	B-cell non-Hodgkin's lymphoma (NHL)
T17	indication 1390 1393	NHL
T18	co-administereddrug 1570 1579	rituximab
T19	dose 1580 1589	250 mg/m2
T20	routeofadministration 1590 1602	intravenous.
T21	co-administereddrug 1647 1656	rituximab
T22	dose 1657 1666	250 mg/m2
T23	routeofadministration 1667 1678	intravenous
T24	co-administereddrug 1754 1763	rituximab
T25	dose 1786 1796	0.4 mCi/kg
T26	dose 1798 1814	14.8 MBq per kg)
T27	activeingredient 1815 1819	Y-90
T28	tradename 1820 1827	Zevalin
T29	routeofadministration 1828 1840	intravenous.
T30	co-administereddrug 1957 1966	rituximab
T31	dose 1988 1998	0.3 mCi/kg
T32	dose 2000 2016	11.1 MBq per kg)
T33	activeingredient 2017 2021	Y-90
T34	tradename 2022 2029	Zevalin
T35	routeofadministration 2030 2042	intravenous.
T36	adversereaction 2328 2355	Serious Infusion Reactions:
T37	co-administereddrug 2380 2389	rituximab
T38	activeingredient 2394 2398	Y 90
T39	tradename 2399 2407	Zevalin.
T40	adversereaction 2429 2461	Prolonged and Severe Cytopenias:
T41	tradename 2480 2487	Zevalin
T42	adversereaction 2602 2647	Severe Cutaneous and Mucocutaneous Reactions:
T43	co-administereddrug 2660 2669	rituximab
T44	tradename 2674 2681	Zevalin
T45	adversereaction 2712 2756	severe cutaneous or mucocutaneous reactions.
T46	adversereaction 2834 2842	Leukemia
T47	adversereaction 2847 2871	Myelodysplastic Syndrome
T48	tradename 3114 3122	Zevalin.
T49	adversereaction 3139 3161	Embryo-fetal Toxicity:
T50	adversereaction 3360 3448	cytopenias, fatigue, nasopharyngitis, nausea, abdominal pain, asthenia, cough, diarrhea,
T51	adversereaction 3453 3461	pyrexia.
T52	company 3513 3543	Spectrum Pharmaceuticals, Inc.
T53	tradename 4251 4258	Zevalin
T54	activeingredient 4352 4356	Y-90
T55	tradename 4357 4364	Zevalin
T56	adversereaction 4528 4554	Serious Infusion Reactions
T57	adversereaction 4559 4590	Prolonged and Severe Cytopenias
T58	adversereaction 4595 4639	Severe Cutaneous and Mucocutaneous Reactions
T59	adversereaction 4691 4726	Myelodysplastic Syndrome, Leukemia,
T60	adversereaction 4827 4848	Embryo-Fetal Toxicity
T61	adversereaction 5733 5793	SERIOUS INFUSION REACTIONS, PROLONGED AND SEVERE CYTOPENIAS,
T62	adversereaction 5798 5871	SEVERE CUTANEOUS AND MUCOCUTANEOUS REACTIONS Serious Infusion Reactions:
T63	co-administereddrug 5913 5922	rituximab
T64	tradename 5963 5970	Zevalin
T65	adversereaction 6030 6147	hypoxia, pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction, ventricular fibrillation,
T66	adversereaction 6151 6169	cardiogenic shock.
T67	co-administereddrug 6216 6225	rituximab
T68	co-administereddrug 6314 6323	rituximab
T69	activeingredient 6328 6332	Y-90
T70	tradename 6333 6340	Zevalin
T71	adversereaction 6375 6434	severe infusion reactions. Prolonged and Severe Cytopenias:
T72	activeingredient 6436 6440	Y-90
T73	tradename 6441 6448	Zevalin
T74	adversereaction 6475 6506	severe and prolonged cytopenias
T75	activeingredient 6544 6548	Y-90
T76	tradename 6549 6556	Zevalin
T77	adversereaction 6717 6809	Severe Cutaneous and Mucocutaneous Reactions: Severe cutaneous and mucocutaneous reactions,
T78	tradename 6841 6848	Zevalin
T79	co-administereddrug 6883 6892	rituximab
T80	activeingredient 6897 6901	Y-90
T81	tradename 6902 6909	Zevalin
T82	activeingredient 7075 7079	Y-90
T83	tradename 7080 7087	Zevalin
T84	dose 7106 7114	32.0 mCi
T85	dose 7116 7125	1184 MBq)
T86	indication 7194 7245	Relapsed or Refractory, Low-grade or Follicular NHL
T87	tradename 7248 7255	Zevalin
T88	indication 7290 7374	relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL).
T89	indication 7380 7415	Previously Untreated Follicular NHL
T90	tradename 7417 7424	Zevalin
T91	indication 7459 7494	previously untreated follicular NHL
T92	tradename 7662 7669	Zevalin
T93	tradename 7741 7748	Zevalin
T94	co-administereddrug 7954 7962	Rituxan/
T95	tradename 7962 7969	Zevalin
T96	tradename 8165 8172	Zevalin
T97	co-administereddrug 8254 8267	acetaminophen
T98	routeofadministration 8275 8281	orally
T99	co-administereddrug 8286 8301	diphenhydramine
T100	routeofadministration 8308 8314	orally
T101	co-administereddrug 8324 8333	rituximab
T102	co-administereddrug 8365 8374	rituximab
T103	dose 8375 8384	250 mg/m2
T104	routeofadministration 8385 8398	intravenously
T105	co-administereddrug 8587 8596	rituximab
T106	co-administereddrug 8647 8656	rituximab
T107	adversereaction 8670 8696	serious infusion reactions
T108	tradename 8717 8724	Zevalin
T109	co-administereddrug 8846 8855	rituximab
T110	adversereaction 8874 8900	severe infusion reactions.
T111	co-administereddrug 9020 9033	acetaminophen
T112	routeofadministration 9041 9047	orally
T113	co-administereddrug 9052 9067	diphenhydramine
T114	routeofadministration 9074 9080	orally
T115	co-administereddrug 9090 9099	rituximab
T116	co-administereddrug 9131 9140	rituximab
T117	dose 9141 9150	250 mg/m2
T118	routeofadministration 9151 9164	intravenously
T119	adversereaction 9307 9325	infusion reactions
T120	co-administereddrug 9342 9351	rituximab
T121	co-administereddrug 9395 9404	rituximab
T122	activeingredient 9556 9560	Y-90
T123	tradename 9561 9568	Zevalin
T124	co-administereddrug 9658 9667	rituximab
T125	activeingredient 9899 9903	Y-90
T126	tradename 9904 9911	Zevalin
T127	routeofadministration 9934 9945	intravenous
T128	activeingredient 9970 9974	Y-90
T129	dose 9975 9989	0.4 mCi per kg
T130	dose 9991 10007	14.8 MBq per kg)
T131	activeingredient 10139 10143	Y-90
T132	tradename 10144 10151	Zevalin
T133	routeofadministration 10175 10186	intravenous
T134	activeingredient 10210 10214	Y-90
T135	dose 10215 10229	0.3 mCi per kg
T136	dose 10231 10247	11.1 MBq per kg)
T137	dose 10299 10305	32 mCi
T138	dose 10307 10316	1184 MBq)
T139	activeingredient 10317 10321	Y-90
T140	tradename 10322 10329	Zevalin
T141	activeingredient 10466 10470	Y-90
T142	tradename 10471 10479	Zevalin.
T143	activeingredient 10670 10674	Y-90
T144	tradename 10675 10682	Zevalin
T145	activeingredient 10743 10760	Yttrium-90 (Y-90)
T146	tradename 10761 10769	Zevalin.
T147	tradename 10840 10847	Zevalin
T148	activeingredient 11029 11039	Yttrium-90
T149	inactiveingredient 11240 11255	Sodium Chloride
T150	activeingredient 11509 11513	Y-90
T151	activeingredient 11563 11567	Y-90
T152	tradename 11568 11575	Zevalin
T153	tradename 11581 11588	Zevalin
T154	inactiveingredient 11601 11615	sodium acetate
T155	activeingredient 11824 11828	Y-90
T156	activeingredient 11902 11906	Y-90
T157	inactiveingredient 11948 11962	Sodium Acetate
T158	activeingredient 12006 12010	Y-90
T159	inactiveingredient 12224 12238	Sodium Acetate
T160	activeingredient 12375 12379	Y-90
T161	tradename 12524 12531	Zevalin
T162	nanoparticle 12533 12554	ibritumomab tiuxetan)
T163	activeingredient 13190 13194	Y90.
T164	activeingredient 13455 13459	Y-90
T165	tradename 13460 13467	Zevalin
T166	activeingredient 13639 13644	Y-90.
T167	activeingredient 13709 13713	Y-90
T168	tradename 13714 13721	Zevalin
T169	dose 13742 13748	32 mCi
T170	dose 13750 13759	1184 MBq)
T171	activeingredient 14039 14049	Yttrium-90
T172	tradename 14050 14057	Zevalin
T173	activeingredient 14277 14282	Y-90.
T174	activeingredient 14384 14388	Y-90
T175	tradename 14389 14397	Zevalin:
T176	activeingredient 14425 14429	Y-90
T177	tradename 14430 14437	Zevalin
T178	inactiveingredient 14750 14755	NaCl)
T179	activeingredient 15177 15181	Y-90
T180	tradename 15182 15189	Zevalin
T181	tradename 15250 15258	Zevalin,
T182	activeingredient 15303 15307	Y-90
T183	tradename 15308 15315	Zevalin
T184	tradename 15484 15491	Zevalin
T185	activeingredient 15851 15855	Y-90
T186	tradename 15856 15863	Zevalin
T187	activeingredient 15873 15877	Y-90
T188	tradename 15878 15885	Zevalin
T189	nanoparticle 17368 17388	ibritumomab tiuxetan
T190	adversereaction 17480 17506	Serious Infusion Reactions
T191	co-administereddrug 17545 17566	rituximab. Rituximab,
T192	tradename 17598 17605	Zevalin
T193	adversereaction 17662 17681	infusion reactions.
T194	co-administereddrug 17731 17740	rituximab
T195	adversereaction 17814 17839	severe infusion reactions
T196	adversereaction 17852 18019	urticaria, hypotension, angioedema, hypoxia, bronchospasm, pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction, ventricular fibrillation,
T197	adversereaction 18024 18042	cardiogenic shock.
T198	co-administereddrug 18077 18086	rituximab
T199	adversereaction 18105 18131	severe infusion reactions.
T200	co-administereddrug 18157 18166	rituximab
T201	activeingredient 18171 18175	Y-90
T202	tradename 18176 18183	Zevalin
T203	adversereaction 18203 18229	severe infusion reactions.
T204	co-administereddrug 18247 18255	Rituxan/
T205	tradename 18255 18262	Zevalin
T206	adversereaction 18401 18444	Prolonged and Severe Cytopenias Cytopenias
T207	adversereaction 18508 18518	hemorrhage
T208	adversereaction 18523 18540	severe infection,
T209	tradename 18593 18600	Zevalin
T210	adversereaction 18690 18706	thrombocytopenia
T211	adversereaction 18711 18722	neutropenia
T212	adversereaction 18766 18782	thrombocytopenia
T213	adversereaction 18895 18905	cytopenias
T214	tradename 19042 19049	Zevalin
T215	tradename 19260 19267	Zevalin
T216	adversereaction 19404 19414	cytopenias
T217	adversereaction 19446 19478	febrile neutropenia, hemorrhage)
T218	tradename 19515 19522	Zevalin
T219	tradename 19631 19638	Zevalin
T220	adversereaction 19665 19805	Severe Cutaneous and Mucocutaneous Reactions Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous dermatitis,
T221	adversereaction 19810 19833	exfoliative dermatitis,
T222	tradename 20006 20013	Zevalin
T223	tradename 20052 20059	Zevalin
T224	adversereaction 20107 20149	severe cutaneous or mucocutaneous reaction
T225	adversereaction 20496 20531	Myelodysplastic Syndrome, Leukemia,
T226	activeingredient 20614 20618	Y-90
T227	tradename 20632 20639	Zevalin
T228	adversereaction 20678 20708	Myelodysplastic syndrome (MDS)
T229	adversereaction 20716 20748	acute myelogenous leukemia (AML)
T230	indication 20797 20823	relapsed or refractory NHL
T231	adversereaction 21045 21048	MDS
T232	adversereaction 21052 21055	AML
T233	tradename 21099 21106	Zevalin
T234	activeingredient 21244 21248	Y-90
T235	tradename 21249 21256	Zevalin
T236	tradename 21319 21326	Zevalin
T237	adversereaction 21473 21480	MDS/AML
T238	tradename 21497 21505	Zevalin,
T239	tradename 21677 21684	Zevalin
T240	adversereaction 21740 21746	Deaths
T241	adversereaction 21754 21761	MDS/AML
T242	tradename 21799 21806	Zevalin
T243	tradename 21937 21944	Zevalin
T244	tradename 22196 22203	Zevalin
T245	tradename 22324 22332	Zevalin.
T246	tradename 22406 22413	Zevalin
T247	tradename 22517 22524	Zevalin
T248	activeingredient 22530 22535	Y-90,
T249	adversereaction 22704 22725	Embryo-Fetal Toxicity
T250	activeingredient 22755 22759	Y-90
T251	tradename 22760 22767	Zevalin
T252	tradename 22836 22843	Zevalin
T253	adversereaction 23241 23267	Serious Infusion Reactions
T254	adversereaction 23333 23364	Prolonged and Severe Cytopenias
T255	adversereaction 23520 23564	Severe Cutaneous and Mucocutaneous Reactions
T256	adversereaction 23630 23638	Leukemia
T257	adversereaction 23643 23667	Myelodysplastic Syndrome
T258	tradename 23743 23750	Zevalin
T259	adversereaction 23755 23843	cytopenias, fatigue, nasopharyngitis, nausea, abdominal pain, asthenia, cough, diarrhea,
T260	adversereaction 23848 23856	pyrexia.
T261	tradename 23895 23902	Zevalin
T262	adversereaction 23907 23938	prolonged and severe cytopenias
T263	adversereaction 23940 23991	thrombocytopenia, anemia, lymphopenia, neutropenia)
T264	tradename 24032 24039	Zevalin
T265	co-administereddrug 24080 24090	rituximab,
T266	co-administereddrug 24123 24133	rituximab.
T267	tradename 24477 24484	Zevalin
T268	indication 24506 24570	relapsed or refractory, low-grade, follicular or transformed NHL
T269	indication 24644 24679	previously untreated follicular NHL
T270	tradename 24744 24751	Zevalin
T271	tradename 24810 24817	Zevalin
T272	indication 24839 24865	relapsed or refractory NHL
T273	dose 24921 24931	0.4 mCi/kg
T274	dose 24933 24945	14.8 MBq/kg)
T275	activeingredient 24949 24953	Y-90
T276	tradename 24954 24961	Zevalin
T277	indication 25001 25027	relapsed or refractory NHL
T278	dose 25106 25116	0.3 mCi/kg
T279	dose 25118 25130	11.1 MBq/kg)
T280	activeingredient 25135 25139	Y-90
T281	tradename 25140 25147	Zevalin
T282	indication 25192 25216	previously untreated NHL
T283	dose 25272 25282	0.4 mCi/kg
T284	dose 25284 25296	14.8 MBq/kg)
T285	activeingredient 25300 25304	Y-90
T286	tradename 25305 25313	Zevalin;
T287	tradename 25355 25363	Zevalin.
T288	tradename 25467 25474	Zevalin
T289	indication 25686 25721	Previously Untreated Follicular NHL
T290	tradename 25739 25746	Zevalin
T291	tradename 25768 25775	Zevalin
T292	adversereaction 25887 25901	Abdominal pain
T293	adversereaction 25916 25924	Diarrhea
T294	adversereaction 25934 25940	Nausea
T295	adversereaction 25966 25974	Asthenia
T296	adversereaction 25988 25995	Fatigue
T297	adversereaction 26005 26027	Influenza-like illness
T298	adversereaction 26036 26043	Pyrexia
T299	adversereaction 26069 26076	Myalgia
T300	adversereaction 26096 26104	Anorexia
T301	adversereaction 26147 26152	Cough
T302	adversereaction 26166 26188	Pharyngolaryngeal pain
T303	adversereaction 26199 26208	Epistaxis
T304	adversereaction 26221 26245	Nervous System Dizziness
T305	adversereaction 26254 26275	Vascular Hypertension
T306	adversereaction 26434 26446	Night sweats
T307	adversereaction 26455 26464	Petechiae
T308	adversereaction 26473 26481	Pruritus
T309	adversereaction 26490 26494	Rash
T310	adversereaction 26537 26547	Bronchitis
T311	adversereaction 26556 26571	Nasopharyngitis
T312	adversereaction 26582 26590	Rhinitis
T313	adversereaction 26599 26608	Sinusitis
T314	adversereaction 26625 26648	Urinary tract infection
T315	adversereaction 26688 26704	Thrombocytopenia
T316	adversereaction 26715 26726	Neutropenia
T317	adversereaction 26737 26743	Anemia
T318	adversereaction 26753 26763	Leukopenia
T319	adversereaction 26774 26785	Lymphopenia
T320	tradename 26909 26924	Zevalin-treated
T321	indication 26939 27011	relapsed or refractory, low-grade, follicular or transformed B-cell NHL.
T322	tradename 27063 27078	Zevalin-treated
T323	indication 27175 27246	Relapsed or Refractory Low-grade, Follicular or Transformed B-cell NHLa
T324	adversereaction 27286 27302	Thrombocytopenia
T325	adversereaction 27309 27320	Neutropenia
T326	adversereaction 27327 27333	Anemia
T327	adversereaction 27340 27350	Ecchymosis
T328	co-administereddrug 27413 27422	rituximab
T329	tradename 27439 27446	Zevalin
T330	adversereaction 27468 27499	Prolonged and Severe Cytopenias
T331	tradename 27637 27644	Zevalin
T332	indication 27728 27750	previously treated NHL
T333	activeingredient 27826 27830	Y-90
T334	tradename 27831 27838	Zevalin
T335	tradename 27922 27929	Zevalin
T336	activeingredient 28095 28099	Y-90
T337	tradename 28100 28107	Zevalin
T338	dose 28114 28124	0.4 mCi/kg
T339	dose 28126 28149	14.8 MBq/kg) 0.3 mCi/kg
T340	dose 28152 28175	11.1 MBq/kg) 0.4 mCi/kg
T341	dose 28178 28190	14.8 MBq/kg)
T342	adversereaction 29164 29174	Cytopenias
T343	tradename 29251 29258	Zevalin
T344	adversereaction 29838 29847	cytopenia
T345	indication 29881 29904	relapsed/refractory NHL
T346	activeingredient 30059 30064	Y-90-
T347	tradename 30064 30071	Zevalin
T348	indication 30191 30214	relapsed/refractory NHL
T349	tradename 30396 30403	Zevalin
T350	tradename 30598 30613	Zevalin-treated
T351	indication 30688 30714	relapsed or refractory NHL
T352	tradename 30744 30751	Zevalin
T353	indication 30801 30827	relapsed or refractory NHL
T354	tradename 30928 30935	Zevalin
T355	adversereaction 30993 31103	urinary tract infection, febrile neutropenia, sepsis, pneumonia, cellulitis, colitis, diarrhea, osteomyelitis,
T356	adversereaction 31108 31142	upper respiratory tract infection)
T357	adversereaction 31194 31249	sepsis, empyema, pneumonia, febrile neutropenia, fever,
T358	adversereaction 31254 31291	biliary stent-associated cholangitis)
T359	tradename 31325 31332	Zevalin
T360	adversereaction 31398 31509	urinary tract infection, bacterial or viral pneumonia, febrile neutropenia, perihilar infiltrate, pericarditis,
T361	routeofadministration 31514 31525	intravenous
T362	adversereaction 31542 31558	viral hepatitis)
T363	adversereaction 31601 31642	bacterial pneumonia, respiratory disease,
T364	adversereaction 31647 31654	sepsis)
T365	tradename 31758 31765	Zevalin
T366	adversereaction 31818 31836	neutropenic sepsis
T367	adversereaction 31843 31959	bronchitis, catheter sepsis, diverticulitis, herpes zoster, influenza, lower respiratory tract infection, sinusitis,
T368	adversereaction 31964 32007	upper respiratory tract infection. Leukemia
T369	adversereaction 32012 32036	Myelodysplastic Syndrome
T370	indication 32061 32085	relapsed/refractory NHL,
T371	adversereaction 32115 32122	MDS/AML
T372	adversereaction 32187 32194	MDS/AML
T373	adversereaction 32341 32348	MDS/AML
T374	adversereaction 32415 32437	MDS/secondary leukemia
T375	adversereaction 32524 32531	MDS/AML
T376	adversereaction 32737 32744	MDS/AML
T377	adversereaction 32872 32879	MDS/AML
T378	activeingredient 32983 32988	Y-90-
T379	tradename 32988 32995	Zevalin
T380	adversereaction 33054 33061	MDS/AML
T381	tradename 33103 33110	Zevalin
T382	tradename 33281 33288	Zevalin
T383	tradename 33757 33764	Zevalin
T384	adversereaction 33836 33930	erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous dermatitis,
T385	adversereaction 33935 33957	exfoliative dermatitis
T386	adversereaction 34025 34047	Infusion site erythema
T387	adversereaction 34052 34062	ulceration
T388	tradename 34220 34227	Zevalin
T389	tradename 34782 34789	Zevalin
T390	tradename 35157 35164	Zevalin
T391	tradename 35550 35558	Zevalin,
T392	tradename 35829 35837	Zevalin.
T393	activeingredient 36139 36143	Y-90
T394	tradename 36144 36151	Zevalin
T395	tradename 36375 36382	Zevalin
T396	tradename 36559 36566	Zevalin
T397	tradename 36753 36760	Zevalin
T398	activeingredient 36865 36869	Y-90
T399	tradename 36870 36878	Zevalin,
T400	tradename 36950 36957	Zevalin
T401	tradename 37093 37100	Zevalin
T402	indication 37191 37214	relapsed/refractory NHL
T403	tradename 37232 37239	Zevalin
T404	tradename 37418 37425	Zevalin
T405	tradename 37483 37491	Zevalin.
T406	adversereaction 37909 37919	cytopenias
T407	dose 38029 38035	32 mCi
T408	dose 38037 38046	1184 MBq)
T409	tradename 38065 38072	Zevalin
T410	nanoparticle 38074 38095	ibritumomab tiuxetan)
T411	corecomposition 38198 38209	ibritumomab
T412	surfacecoating 38234 38364	tiuxetan [N-[2-bis(carboxymethyl)amino]-3-(pisothiocyanatophenyl)-propyl]-[N-[2-bis(carboxymethyl)amino]-2-(methyl)-ethyl]glycine.
T413	activeingredient 38460 38471	Yttrium-90.
T414	nanoparticle 38509 38529	ibritumomab tiuxetan
T415	molecularweight 38533 38540	148 kD.
T416	tradename 38565 38572	Zevalin
T417	corecomposition 38576 38588	ibritumomab,
T418	corecomposition 38591 38628	murine IgG1 kappa monoclonal antibody
T419	nanoparticle 38664 38684	Ibritumomab tiuxetan
T420	nanoparticle 38838 38858	ibritumomab tiuxetan
T421	inactiveingredient 38875 38891	Sodium Chloride.
T422	activeingredient 38934 38949	Y-90 Yttrium-90
T423	activeingredient 39202 39206	Y-90
T424	activeingredient 39255 39259	Y-90
T425	activeingredient 39424 39428	Y-90
T426	activeingredient 39485 39489	Y-90
T427	activeingredient 39690 39694	Y-90
T428	nanoparticle 40122 40142	Ibritumomab tiuxetan
T429	nanoparticle 40275 40295	ibritumomab tiuxetan
T430	indication 40442 40479	B-cell non-Hodgkin's lymphomas (NHL).
T431	surfacecoating 40592 40601	tiuxetan,
T432	activeingredient 40622 40627	Y-90,
T433	corecomposition 40652 40664	ibritumomab.
T434	activeingredient 40689 40693	Y-90
T435	nanoparticle 40789 40809	Ibritumomab tiuxetan
T436	tradename 41121 41128	Zevalin
T437	tradename 41830 41837	Zevalin
T438	dose 41839 41844	5 mCi
T439	dose 41846 41854	185 MBq]
T440	dose 41863 41869	1.6 mg
T441	nanoparticle 41870 41891	ibritumomab tiuxetan)
T442	tradename 42045 42052	Zevalin
T443	dose 42142 42151	1.0 mg/kg
T444	dose 42155 42165	2.5 mg/kg)
T445	tradename 42174 42181	Zevalin
T446	tradename 42277 42284	Zevalin
T447	tradename 42395 42402	Zevalin
T448	activeingredient 42457 42461	Y-90
T449	eliminationhalflife 42484 42493	30 hours,
T450	auc 42586 42595	39 hours.
T451	tradename 42955 42962	Zevalin
T452	tradename 43023 43030	Zevalin
T453	tradename 43241 43248	Zevalin
T454	tradename 43429 43436	Zevalin
T455	tradename 44047 44054	Zevalin
T456	tradename 44112 44119	Zevalin
T457	co-administereddrug 44160 44170	rituximab,
T458	indication 44541 44545	NHL,
T459	co-administereddrug 44659 44668	rituximab
T460	tradename 45162 45169	Zevalin
T461	indication 45252 45328	relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma (NHL);
T462	co-administereddrug 45359 45369	rituximab.
T463	indication 45480 45484	NHL,
T464	tradename 45594 45601	Zevalin
T465	co-administereddrug 45648 45657	rituximab
T466	routeofadministration 45670 45672	IV
T467	dose 45685 45698	375 mg per m2
T468	frequency 45699 45705	weekly
T469	tradename 45853 45860	Zevalin
T470	tradename 46091 46098	Zevalin
T471	tradename 46128 46135	Zevalin
T472	indication 46489 46537	relapsed or refractory low-grade, follicular NHL
T473	activeingredient 46841 46845	Y-90
T474	tradename 46846 46853	Zevalin
T475	dose 46855 46869	0.3 mCi per kg
T476	dose 46871 46887	11.1 MBq per kg)
T477	indication 47110 47132	Follicular, B-Cell NHL
T478	indication 47261 47275	follicular NHL
T479	tradename 47660 47667	Zevalin
T480	activeingredient 47708 47712	Y-90
T481	tradename 47713 47720	Zevalin
T482	indication 47995 48017	non-Hodgkin's Lymphoma
T483	co-administereddrug 48482 48502	rituximab-containing
T484	tradename 48613 48628	Zevalin-treated
T485	activeingredient 49190 49194	Y-90
T486	tradename 49208 49215	Zevalin
T487	tradename 49428 49435	Zevalin
T488	nanoparticle 49459 49479	ibritumomab tiuxetan
T489	inactiveingredient 49493 49508	Sodium Chloride
T490	inactiveingredient 49560 49574	Sodium Acetate
T491	inactiveingredient 49599 49624	Sodium Acetate trihydrate
T492	inactiveingredient 49633 49638	Water
T493	inactiveingredient 49745 49752	Albumin
T494	inactiveingredient 49768 49784	Sodium Chloride,
T495	inactiveingredient 49791 49830	Sodium Phosphate Dibasic Dodecahydrate,
T496	inactiveingredient 49836 49850	Pentetic Acid,
T497	inactiveingredient 49856 49885	Potassium Phosphate Monobasic
T498	inactiveingredient 49895 49913	Potassium Chloride
T499	inactiveingredient 49923 49928	Water
T500	activeingredient 50032 50042	Yttrium-90
T501	activeingredient 50142 50146	Y-90
T502	tradename 50147 50154	Zevalin
T503	co-administereddrug 50160 50169	Rituximab
T504	company 50180 50191	Biogen Idec
T505	company 50196 50210	Genentech USA)
T506	adversereaction 50499 50518	infusion reactions.
T507	adversereaction 50685 50695	cytopenias
T508	adversereaction 50697 50731	bleeding, easy bruising, petechiae
T509	adversereaction 50735 50760	purpura, pallor, weakness
T510	adversereaction 50765 50773	fatigue)
T511	adversereaction 51025 51038	rash, bullae,
T512	adversereaction 51042 51081	desquamation of the skin or oral mucosa
T513	adversereaction 51165 51174	infection
T514	adversereaction 51181 51189	pyrexia)
T515	tradename 51321 51328	Zevalin
T516	tradename 51495 51502	Zevalin
T517	tradename 51670 51677	Zevalin
T518	tradename 51729 51736	Zevalin
T519	nanoparticle 51738 51759	ibritumomab tiuxetan)
T520	company 51780 51810	Spectrum Pharmaceuticals, Inc.
T521	tradename 51874 51881	Zevalin
T522	company 51911 51941	Spectrum Pharmaceuticals, Inc.
T523	u.s.patent 51994 52102	5,736,137, 5,776,456, 5,843,439, 6,207,858, 6,399,061, 6,682,734, 6,994,840, 7,229,620, 7,381,560, 7,422,739
